In 2024, the Medsintez Plant in collaboration with Tonghua Anrate Biopharmaceutical Co. launched the production of the substance and finished dosage forms of the world's first registered drug of recombinant human albumin. The drug was obtained using Pichia Pastoris cells by the recombinant DNA technology.

The Medsintez Plant has participated in an international business meeting with the delegation from the United Arab Emirates as part of the INNOPROM 2024 business program in Ekaterinburg. The meeting with representatives of the national Ministry of Industry, pharmaceutical and medical industries of the UAE was organized by the Ministry of Industry and Trade of the Russian Federation. The meeting was attended by the Deputy Minister of Industry and Advanced Technology of the UAE, representatives of Globalpharma, SayGen, Hayat Biotech, Abu Dhabi Medical Devices.

The 5th (XXX) National Congress of Endocrinologists "Innovative Technologies in Endocrinology" with international participation was held in Moscow from May 21 to 24, 2024, organized by the Russian Association of Endocrinologists and National Medical Research Center for Endocrinology, Federal State Budgetary Institution of the Russian Ministry of Health. Among the leading domestic and foreign pharmaceutical manufacturers, the Medsintez Plant presented its key products at the booth—genetically engineered and analogue human insulins Rosinsulin. Medical specialists who visited the exhibition expressed gratitude to the company for the affordability and high quality of its products.